No Data
Puruis (301257.SZ): Currently not participating in any clinical research projects related to Brain-computer Interface.
On December 19, Gelonghui reported that Pruess (301257.SZ) stated on the investor interaction platform that the company is currently not involved in any clinical research projects related to Brain-computer Interface, and the company will continue to pay attention to Industry trends and customer needs.
gelonhui announcement selection | shanghai new world: the proportion of pan-second-dimensional format in the company's overall business sector is very small; guangxi liugong machinery: plans to spend 0.3 billion yuan-0.6 billion yuan to repurchase shares
【Hotspot Tracking】Shenzhen Kingdom Sci-Tech (600446.SH): Plans to sell all 14.4 million shares of Xing Wang Xin Tong. Shanghai New World (600628.SH): The pan-Subculture sector accounts for a very small proportion of the company's overall business sector. Zhejiang XCC Group (603667.SH): The screw rod product market is still in its preliminary stage, and currently, orders have little impact on the company's performance. 【Project Investment】China Shipbuilding Special Gas (688146.SH): Plans to invest 9.81 million yuan to construct a comprehensive workshop for cylinder grinding and regular inspection. China Shipbuilding Special Gas (688146.SH): Plans to invest 15.97 million yuan to build in the Feixiang District of Handan City.
Shaky Earnings May Not Tell The Whole Story For SMO ClinPlusLTD (SZSE:301257)
Prius: Third quarter report 2024
Puresis (301257.SZ) released its performance for the first three quarters, with a net income of 72.2643 million yuan, a decrease of 28.39%.
Puresis (301257.SZ) released the third quarter report of 2024. The company's revenue for the first three quarters was 5....
Pruess (301257.SZ) net income in the first three quarters was 72.2643 million yuan, a decrease of 28.39% year-on-year.
Grace Times reported on October 29th that Prose (301257.SZ) released the third quarter report of 2024, with the company achieving revenue of 0.594 billion yuan in the first three quarters, a year-on-year increase of 9.17%; net income of 72.2643 million yuan, a year-on-year decrease of 28.39%. Among them, the third quarter achieved revenue of 0.199 billion yuan, a year-on-year increase of 2.03%; net income of 17.3413 million yuan, a year-on-year decrease of 55.50%.
Is SMO ClinPlus CO.,LTD.'s (SZSE:301257) Recent Stock Performance Tethered To Its Strong Fundamentals?
